frontiers in Immunology

CORRECTION
published: 13 November 2017
doi: 10.3389/fimmu.2017.01582

Corrigendum: Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins

Ji-Hee Ha[1], *Jung-Eun Kim*[1] *and Yong-Sung Kim*[1,2]*

[1] *Department of Molecular Science and Technology, Ajou University, Suwon, South Korea,* [2] *Department of Applied Chemistry and Biological Engineering, College of Engineering, Ajou University, Suwon, South Korea*

Keywords: bispecific antibody, Fc engineering, heterodimeric Fc, Fc-fusion proteins, immunocytokines, antibody engineering

A corrigendum on

Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins
by Ha J-H, Kim J-E, Kim Y-S. Front Immunol (2016) 7:394. doi: 10.3389/fimmu.2016.00394

In the original article, there was an error [wrong description on LY3164530 (Eli Lilly) antibody in the last paragraph of page 9 of original article].

A correction has been made to section "HETERODIMERIC Fc-BASED ANTIBODIES IN DIVERSE FORMATS", subsection "Intact IgG Formats with Correct LC Association", sixth Paragraph (line 8–12 of the sixth paragraph) (In the last paragraph of page 9 of original article):

An alternative approach for enforcing correct $HC_{VH\text{-}CH1}$–LC association includes introduction of a set of mutations at the heterodimeric VL–CL and VH–CH1 interface (18, 66, 67), similar to modification of the CH3 interface for the heterodimeric Fc design. In an ortho-Fab IgG approach (18), structure-based regional design introduced complementary mutations at the LC and $HC_{VH\text{-}CH1}$ interface in only one Fab, without any changes being made to the other Fab (Figure 3). Zymeworks is currently developing intact IgG-format bsAbs generated by the combination of ortho-Fab IgG and ZW1 Fc technologies (http://www.zymeworks.com/).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

OPEN ACCESS

Edited and Reviewed by:
Tianlei Ying,
Fudan University, China

***Correspondence:**
Yong-Sung Kim
kimys@ajou.ac.kr

Specialty section:
This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology

Received: *19 October 2017*
Accepted: *02 November 2017*
Published: *13 November 2017*

Citation:
Ha J-H, Kim J-E and Kim Y-S (2017) Corrigendum: Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins. Front. Immunol. 8:1582. doi: 10.3389/fimmu.2017.01582